Related Experiment Video
Updated: Jun 20, 2026
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
Published on: September 25, 2017
USP11 alleviates pathological cardiac hypertrophy via stabilizing SIRT6
Xijia Wang1,2, Wenzhe Zong1,2, Di Zhou1,2
1Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Insights
USP11 deubiquitinase protects against cardiac hypertrophy by stabilizing SIRT6 and inhibiting the IGF2-AKT pathway. Targeting this USP11-SIRT6 axis offers a potential therapy for heart failure and cardiac remodeling.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Pathological cardiac hypertrophy precedes heart failure.
- Protein ubiquitination/deubiquitination regulates cardiomyocyte homeostasis.
- The role of USP11 in cardiac function was previously unknown.
Purpose of the Study:
- To investigate USP11's role in cardiac hypertrophy.
- To explore USP11's downstream molecular mechanisms in the heart.
Main Methods:
- Assessed USP11 expression in mouse hearts post-TAC and in PE-stimulated cardiomyocytes.
- Utilized AAV9 to overexpress USP11 in cardiomyocytes.
- Evaluated cardiac remodeling and function via echocardiography, histology, and molecular analyses.
- Performed co-IP, mass spectrometry, and ubiquitination assays to study USP11-SIRT6 interaction.
Main Results:
- USP11 expression decreased in hypertrophic hearts and cardiomyocytes.
- USP11 overexpression alleviated cardiac hypertrophy, fibrosis, and improved function in mice.
- USP11 stabilized SIRT6 by removing K48-linked ubiquitin chains, preventing proteasomal degradation.
- USP11 inhibited the IGF2-AKT pathway via SIRT6 stabilization; USP11 deficiency had opposite effects.
- SIRT6 reintroduction rescued hypertrophy caused by USP11 deficiency.
Conclusions:
- USP11 acts as a protective deubiquitinase in cardiac hypertrophy.
- USP11 stabilizes SIRT6, inhibiting the SIRT6-regulated IGF2-AKT signaling axis.
- The USP11-SIRT6 pathway is a potential therapeutic target for heart failure and cardiac remodeling.
Background:
Pathological cardiac hypertrophy is a key precursor to heart failure. Protein ubiquitination and deubiquitination are crucial mechanisms controlling cardiomyocyte signaling homeostasis. USP11, a ubiquitin-specific protease, has been implicated in multiple cellular regulatory processes, but its cardiac function remains unknown. Here, we investigated whether USP11 modulates cardiac hypertrophy and explored its downstream molecular mechanisms.
Methods:
USP11 expression was detected in hearts from mice subjected to transverse aortic constriction (TAC) and in phenylephrine (PE)-stimulated cardiomyocytes. Cardiomyocyte-specific overexpression of USP11 was achieved using AAV9-cTnT-USP11. The effects of USP11 on cardiac remodeling and function were evaluated by echocardiography, histology, and molecular analyses. Neonatal rat ventricular cardiomyocytes (NRVMs) were used for in vitro assays. Co-immunoprecipitation (co-IP), mass spectrometry, and ubiquitination assays were performed to explore the interaction between USP11 and SIRT6 and its mechanistic consequences.
Results:
USP11 expression was markedly decreased in hypertrophic mouse hearts and PE-treated NRVMs. Cardiomyocyte-specific overexpression of USP11 significantly alleviated TAC-induced cardiac hypertrophy and fibrosis, improving left ventricular function. In NRVMs, USP11 overexpression mitigated PE-induced cardiomyocyte hypertrophy, whereas USP11 silencing aggravated hypertrophy. Mechanistically, USP11 directly bound to and stabilized SIRT6 by removing its K48-linked ubiquitin chains, thereby preventing its proteasomal degradation. USP11 attenuated the activation of the IGF2-AKT signaling pathway by stabilizing SIRT6, while the absence of USP11 had the opposite effect. Mutation of the catalytic site of USP11 abolished both its effect on SIRT6 stabilization and its ability to attenuate cardiac hypertrophy. Furthermore, reintroduction of SIRT6 rescued the pro-hypertrophic effects of USP11 deficiency.
Conclusions:
USP11 acts as a protective deubiquitinase in pathological cardiac hypertrophy by stabilizing SIRT6 and inhibiting the SIRT6-regulated IGF2-AKT signaling axis. Targeting the USP11-SIRT6 pathway may represents a potential therapeutic target for preventing maladaptive cardiac remodeling and heart failure.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Heart Failure II: Pathophysiology
01:26Cellular Adaptation II: Hypertrophy
01:29Cardiomyopathy V: Interprofessional Care
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:17Pathophysiology of Heart Failure